Research Use Only (RUO). This article is for education and shares what published science says about a research compound. It is not medical advice, and nothing here is a suggestion to use any peptide on people or animals.
Searches like retatrutide dosing, retatrutide dosage, retatrutide dose schedule, and retatrutide dosage chart are asking one thing: what amounts did researchers actually study? Below is what the published clinical trials reported. This is trial data for education only. It is not a dose recommendation, and Dissolv Labs products are Research Use Only.
What doses were studied in the trials?
In the Phase 2 trial published in the New England Journal of Medicine, retatrutide was given to participants once per week by subcutaneous injection at 1 mg, 4 mg, 8 mg, and 12 mg. In the Phase 3 TRIUMPH program, the highest target amounts studied were the 9 mg and 12 mg weekly levels. These are the amounts tested by researchers in a controlled study setting.
What is a titration schedule?
In the trials, participants did not start at the top amount. Researchers used a slow step-up, called titration, starting low and increasing over several weeks. This approach was linked in the reports to fewer stomach-related side effects during the early weeks. The exact step-up plan was set by the trial protocol.
Why researchers report a weekly schedule
Retatrutide was studied as a once-weekly peptide. A long action time is one reason the trials used a weekly design. Understanding how a weekly schedule affects levels in the body is a common question in metabolic peptide research.
Important: this is not dosing guidance
The numbers above describe what happened inside published clinical trials in human participants under medical supervision. They are shared here as factual research history. Nothing here tells anyone to use retatrutide, and the compound is not approved for use outside of a trial.
Retatrutide research materials at Dissolv Labs
Dissolv Labs supplies high-purity compounds as reference materials for laboratory research only. They are not for human or animal use.
Frequently asked questions
What was the highest retatrutide dose studied?
The 12 mg once-weekly level was the highest reported in the Phase 2 and Phase 3 trials.
Why did trials start at a low amount?
A slow step-up (titration) was linked in the reports to milder gastrointestinal side effects early on.
Is there an official retatrutide dosage chart?
No approved chart exists, because retatrutide is not FDA approved. Only trial protocols define the amounts studied.
The bottom line
Published trials studied retatrutide at 1, 4, 8, and 12 mg once weekly, with a slow step-up. This is research history, not advice, and retatrutide remains investigational.
Sources
- Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (NEJM, via PubMed)
- Eli Lilly: Phase 2 retatrutide results published in NEJM
- Eli Lilly: Retatrutide Phase 3 (TRIUMPH) topline results
- Drugs.com: Retatrutide history and FDA approval status
Disclaimer: All Dissolv Labs products are sold for Research Use Only and are not for human or veterinary use. This content is educational and is not medical advice, diagnosis, treatment guidance, or a recommendation to consume any substance.
